Abstract
The FDA alerts to potential T cell malignancy risks linked to CAR T therapies targeting CD19/BCMA, recognizing their advantages but advocating vigilant monitoring. Influential factors in secondary T cell malignancy encompass viral vectors, CAR design, and patient genetics. Analytical findings highlight instances of T cell cancer, stressing the necessity for prolonged safety studies and refined CAR T strategies. Global collaboration is crucial for consistent reporting and adherence to treatments. Recommendations include extended safety assessments, refined CAR T strategies, enhanced data reporting, and global cooperation. This viewpoint addresses safety concerns regarding CAR T therapies and proposes measures to enhance their safety and effectiveness. The discussion emphasizes the importance of optimizing CAR T strategies to minimize risks and elevate treatment outcomes
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
